Intersect ENT, Inc. (NASDAQ:XENT) will be discussing 3Q20 financial results with the investment community.on 2nd November 2020 at 8:30 AM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.intersectent.com
Earnings Expectation
Intersect ENT, Inc. is reporting third quarter financial results on Monday 2nd November 2020, before market open.
According to analysts surveyed by Thomson Reuters, XENT is expected to report 3Q20 loss of $ 0.45 per share from revenue of $ 21.80 million.
For the full year, analysts anticipate top line of $ 80.39 million, while looking forward to loss of $ 1.98 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 22.40 million ~ $ 22.80 million
Full Year 2020 topline are forecasted in a range of$ 115.00 million ~ $ 119.00 million
Click Here For More Historical Outlooks Of Intersect ENT, Inc.
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting.
